

Citation for the published version:

El-Kateb, S., Sridharan, S., Farrington, K., Fan, S., & Davenport, A. (2016). A single weekly Kt/Vurea target for peritoneal dialysis patients does not provide an equal dialysis dose for all. *Kidney international*, 90(6), 1342-1347.
<https://doi.org/10.1016/j.kint.2016.07.027>

Document Version: Accepted Version

This manuscript is made available under the CC-BY-NC-ND license
<https://creativecommons.org/licenses/by-nc-nd/4.0/>

Link to the final published version available at the publisher:

<https://doi.org/10.1016/j.kint.2016.07.027>

General rights

Copyright© and Moral Rights for the publications made accessible on this site are retained by the individual authors and/or other copyright owners.

Please check the manuscript for details of any other licences that may have been applied and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (<http://uhra.herts.ac.uk/>) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Take down policy

If you believe that this document breaches copyright please contact us providing details, any such items will be temporarily removed from the repository pending investigation.

Enquiries

Please contact University of Hertfordshire Research & Scholarly Communications for any enquiries at rsc@herts.ac.uk

1 A single weekly Kt/Vurea target for peritoneal dialysis patients does not provide
2 an equal dialysis dose for all

3

4 Sally El-Kateb MD¹, Sivakumar Sridharan PhD², Ken Farrington FRCP^{2,3}, Stanley
5 Fan⁴, Andrew Davenport FRCP¹

6

7 ¹ UCL Centre for Nephrology, Royal Free Hospital, University College London
8 Medical School, Rowland Hill Street, London NW3 "QG, UK

9 ²Renal Unit, Lister Hospital, Coreys Mill Lane Stevenage SG1 4AB, UK

10 ³ University of Hertfordshire, College Lane Hatfield AL10 9AB, UK

11 ⁴ Barts Health NHS Trust, Whitechapel Rd, London E1 1BB, UK

12

13 Sally El-Kateb	sallyelkateb@yahoo.com
14 Sivakumar Sridharan	sivakumar.sridharan@nhs.net
15 Ken Farrington	ken.farrington@nhs.net
16 Stanley Fan	fan.stanley@nhs.net
17 Andrew Davenport	andrewdavenport@nhs.uk

18

19

20 Address for correspondence

21 Andrew Davenport andrewdavenport@nhs.net

22

23 contact andrewdavenport@nhs.net

24 UCL Centre for Nephrology, Royal Free Hospital, University College London

25 Medical School, Rowland Hill Street, London NW3 2PF

26 tel 44-2074726457 fax 44-2073178591

27

28

29 short title resting and total energy expenditure in peritoneal dialysis patients

30

31 key words	peritoneal dialysis	resting energy expenditure
32	total energy expenditure	total body water body surface
33 area	Kt/Vurea	

34

35 word count	abstract	250
36	body	2178
37	figures	3
38	tables	3
39	references	31

40

41 Funding grant -British Renal Society, Dr El-Kateb was awarded an

42 International Society for Nephrology fellowship

43 No author has any conflict of interest

44 Abstract

45 Dialysis adequacy is traditionally based on urea clearance, adjusted for
46 total body volume (Kt/Vurea), and clinical guidelines recommend a Kt/Vurea
47 target for peritoneal dialysis (PD). We wished to determine whether adjusting
48 dialysis dose by resting (REE) and total energy expenditure (TEE), would alter
49 the delivered dialysis dose.

50 We determined REE and TEE by equations based on doubly labelled
51 isotopic water studies, and adjusted Kt_{urea} for REE and TEE.

52 We studied 148 PD patients, 97 male (65.5%), 54 diabetic (36.5%), mean
53 age 60.6±17.6 years. The mean REE was 1534±241 kcal/day and TEE 1974±414
54 kcal/day. Adjusting Kt for REE showed a reduced delivered dialysis dose (ml
55 /kcal/day) for women vs men (5.5±0.4 vs 6.2±0.6), age < 65 vs > 65 years
56 (5.6±0.56 vs 6.4±0.5), weight < 65 kg vs >80 kg (5.8±0.6 vs 6.1±0.5), low co-
57 morbidity vs high co-morbidity (6.2±0.6 vs 5.9±0.6), all p<0.01. Adjusting for TEE
58 showed reduced dosing for those employed vs no employment (4.3±0.7 vs
59 4.8±0.8), low frailty vs high frailty score (4.5±0.8 vs 5.0±0.7), both p<0.01.

60 Adjusting the dialysis target dose for REE shows that for the same Kt
61 urea, women, younger, smaller and less co-morbid patients would all receive less
62 dialysis, and adjusting for TEE additionally shows that those employed and
63 physically fitter would receive less dialysis. The current paradigm for a single
64 target Kt/Vurea for all PD patients does not take into account energy
65 expenditure and metabolic rate, and may lead to lowered dialysis delivery for
66 the younger more active female patient.

67

68 Introduction

69 More than 2 million patients with end stage kidney disease are currently
70 treated by dialysis worldwide, with around 300,000 treated by peritoneal
71 dialysis. As with for haemodialysis, there are clinical guidelines recommending
72 that patients receive a minimal amount of dialysis based on urea clearance [1].
73 These urea based clearance targets are derived from observational studies [2].
74 However prospective studies comparing different peritoneal dialysis regimes
75 designed to achieve different urea clearance targets consistently failed to
76 demonstrate any advantage for greater urea clearance, in terms of patient
77 morbidity or mortality [3-5]. Indeed peritoneal dialysis technique and patient
78 survival have been linked to preservation of residual renal function [6], rather
79 than peritoneal dialysis urea clearance [7].

80 The amount of urea clearance, Kt/V_{urea} , for dialysis patients are
81 currently based on volume of distribution of urea, total body water (TBW)
82 derived from anthropomorphic measurements [8]. However total body water
83 varies with body composition, as some tissues, such as muscle contain more
84 water than fat [9], and also varies between racial groups [10], and patients with
85 diabetes and other co-morbidities [11]. As such for the same Kt/V_{urea} , the
86 delivered urea clearance has been suggested to differ between patients [12].

87 Rather than dosing the amount of dialysis required on urea clearance
88 based on volume of distribution, an alternative approach based upon metabolic
89 activity has been proposed [13]. Urea is generated as a by-product of

90 intracellular nitrogen metabolism. Total body metabolic activity is a composite of
91 resting metabolic rate and that due to physical activity. Previous studies in
92 peritoneal dialysis patients have concentrated on measuring resting energy
93 expenditure (REE) [14,15], but this under estimates total energy expenditure
94 (TEE), by excluding that due to activity energy expenditure (AEE),

95 We recently validated an assessment of TEE, and REE in dialysis patients
96 using a patient self-reported questionnaire and double isotopic labelled water
97 [16]. To establish whether there is a difference in the amount of dialysis
98 delivered for a fixed Kt/Vurea target, we calculated urea clearance adjusted
99 for energy expenditure, to determine whether some groups of patients would be
100 disadvantaged under current clinical guideline recommendations.

101

102 Patients and methods

103 Adult patients with end stage kidney disease established on
104 peritoneal dialysis were recruited from University College London partner
105 hospitals when attending for outpatient assessments of peritoneal dialysis
106 adequacy. Corresponding spent dialysate effluent, 24 hour urine collections and
107 serum samples were analysed by standard methods, and weekly dialysis dose
108 calculated as Kt/Vurea. Protein Nitrogen Appearance rate was estimated using
109 the Bergström equation, and normalised for body weight (nPNA) g/kg/day [17].
110 Patient demographics were obtained from computerised hospital records and
111 comorbidity determined using a self-administered co-morbidity grading [18], and
112 a recognised frailty score [19].

113 Total body water was calculated using the Watson equation [20]. In
114 addition we measured total body water by bioimpedance (InBody 720, InBody,
115 Seoul, South Korea; Body Composition Monitor (BCM), Fresenius, Bad Homberg,
116 Germany) which was performed in a standardised manner in 118 patients [21,22].
117 Bioimpedance measurements made by the BCM and InBody were standardised
118 using previously derived equations [23]. Body surface area was calculated using
119 the Gehan and George equation as recommended by the European Best Clinical
120 Practice guidelines [24].

121 Physical activity data was obtained using the Recent Physical Activity
122 Questionnaire (RPAQ) [16], which collects information about both activity and
123 the time spent performing activities over the preceding four weeks;
124 encompassing activities performed at home, work and during leisure time. The
125 RPAQ has been validated against doubly labelled water technique in general
126 population [16], and has been shown to be a reliable tool for estimation of energy
127 expenditure in patients with chronic kidney disease [25]. Physical activity data
128 was determined by each reported activity being assigned a Metabolic Equivalent
129 of Task (MET) value according to the Compendium of Physical Activities [26].
130 The equations for calculating REE and TTE are detailed in the Appendix.

131 UK clinical guidelines recommend a minimum weekly Kt/V of 1.7 [1]. Hence,
132 in order to compare minimum dialysis targets using alternative scaling
133 parameters, weekly Kt was calculated as $Kt = 1.7 * V$. Corresponding target
134 values of Kt/BSA, Kt/REE and Kt/TEE were calculated by dividing daily Kt by
135 the respective parameters.

136 Ethical approval was granted by the UK National Research Ethics
137 Committee - Essex and the study was registered in UK Clinical Research
138 Network (CRN) Portfolio number 14018. All patients provided written informed
139 consent in keeping with the declaration of Helsinki.

140

141 Statistical analysis

142 Statistical analysis was by students' t test, or Mann Whitney U test,
143 ANOVA and Kruskal Wallis , with appropriate post hoc correction, Pearson or
144 Spearman's test for univariate correlation (GraphPad Prism version 6.0, San
145 Diego, USA) and step backward linear regression, of variables on univariate
146 analysis of $p < 0.1$, with log transformation of variables which were not normally
147 distributed, and removal of variables which were not statistically significant
148 unless they improved model fit, and models were checked for collinearity (SPSS
149 version 22, University of Chicago, Illinois, USA), and Bland Altman comparison
150 (Analyse-It version 3.0, Leeds, UK). Data are presented as mean \pm standard
151 deviation, median (inter quartile range), or mean and 95% confidence limits (CL),
152 or as a percentage.

153

154 Results

155 We studied 148 patients, 97 male (65.5%), 54 diabetic (36.5%), mean age
156 60.6 ± 17.6 years, with a median duration of peritoneal dialysis 9.1 (3.5-25.2)
157 months. The median co-morbidity score was 2 (0-3.8), and frailty score 4 (2-5).
158 43.2% of patients were Caucasian, 27.1% African-Afro-Caribbean, 24.3% South

159 Asian, and 5.4% Far Asian. A minority, 20.3% of patients had some form of
160 employment.

161 Mean haemoglobin was 109.9 ± 14.8 g/l, with a serum albumin 36.5 ± 5.5 g/l
162 and serum C reactive protein (CRP) 6 (2-16) mg/l. Mean weight of the cohort was
163 73.6 ± 16.7 kg, BMI 26.0 ± 4.9 kg/m², and BSA 1.86 ± 0.24 m². The majority of
164 patients were treated by automated peritoneal dialysis cyclers (APD) 85.8% vs
165 14.2% by continuous ambulatory peritoneal dialysis (CAPD). The median total
166 weekly Kt/Vurea was 2.15 (1.8-2.71), with a median 24 hour urine volume of 946
167 (450-1249) ml/day. The mean REE was 1534 ± 241 kcal/day and TEE 1974 ± 414
168 kcal/day. Mean PNA was 64.5 ± 19.7 g/day and nPNA 0.89 ± 0.26 g/kg/day.

169 Male patients were heavier than female (77.0 ± 15.6 vs 72.6 ± 16.6 kg), and
170 had greater REE and TEE (table 1). Patients who were employed, those with
171 greater weight, and greater PNA had higher TEE (Table1), whereas those with
172 greater frailty and co-morbidity, and those who were diabetic and Asian
173 patients tended to have lower TEE.

174 We then adjusted a weekly Kt_{urea} of 1.7 for all patients for both BSA
175 and TBW. Bland Altman analysis showed that for both men and women the
176 adjusted Kt_{urea} was greater for smaller patients with a relatively greater BSA
177 to TBW, and lower for larger patients with a relatively lower BSA compared to
178 TBW (Figure 1).

179 In a subset of 118 (79.7%) of the study group; 75 male (63.6%), 33
180 diabetic (28.5%), mean age 59.3 ± 18.2 years, with a median duration of peritoneal
181 dialysis 9.4 (3.8-25.5) months, we also measured TBW by bioimpedance. The

182 mean weight of this cohort was 73.1 ± 16.6 kg with a body mass index of 26.0 ± 4.9
183 kg/m^2 , with a median co-morbidity grade of 2 (0-4) and frailty score of 4 (2-5),
184 and did not differ from the main study group. There was no significant
185 difference in TBW: Watson equation 40.3 ± 6.1 vs bioimpedance 40.6 ± 3.4 L, mean
186 difference on Bland Altman analysis 0.72 L (Figure 2). There were positive
187 correlations between BSA and both REE and TEE ($r=0.92$, $p<0.001$ and $r=0.59$,
188 $p<0.001$) and also between TBW and both REE and TEE ($r=0.85$, $p<0.001$ and
189 $r=0.62$, $p<0.001$) respectively.

190 We then calculated Kt values for a prescribed Kt/V of 1.7 using for
191 both Watson and bioimpedance estimates of TBW. These values were then
192 patients from adjusted by BSA, REE and TEE. The results are shown in Table 2
193 and Figure 3 for different patient groups. For the same prescribed dialysis dose,
194 women, younger patients, those employed and those weighing less (Figure 3)
195 received less dialysis than men, older patients, those not employed and heavier
196 patients (table 2). In addition generally patients with less co-morbidity and
197 frailty and non-Asian races also tended to receive less dialysis than those who
198 were more co-morbid, frail and of Asian ethnicity.

199 We used a step backward approach to develop multivariable models of
200 adjusted Kt, including all variables with $p<0.1$ on univariate analysis, and then
201 eliminating variables which were not significant or did not improve model fit to
202 determine associations with adjusted dialysis dose. Sex was a significant
203 predictor of Kt/BSA. Sex and age were significant predictors of Kt/REE. the
204 predominant variables (table 3). For Kt/TEE, sex, age and employment were

205 common predictive factors whether Kt was derived using TBW derived by
206 Watson and bioimpedance methods. Both high co-morbidity, and diabetes were
207 additional predictive factors for TEE adjusted using the Watson formula for
208 TBW (table 3).

209

210

211 Discussion

212 Traditionally the target dialysis for patients with end stage kidney
213 failure has been based on urea clearance adjusted for total body water volume.
214 However multiple prospective trials have failed to show an association between
215 greater peritoneal dialysis urea clearance and survival [3,4,7]. Cellular
216 metabolism, in particular protein turnover generates waste products which
217 accumulate in patients with end stage kidney failure. As these azotaemic toxins
218 are generated by cellular metabolism, it has been suggested that the amount of
219 dialysis required for patients should be based on metabolic rate, rather than
220 urea clearance [2]. Studies to-date have concentrated on measuring resting
221 metabolic rate [3], but this ignores physical activity, and as such potentially
222 under estimates energy expenditure. We used equations based on patient self-
223 reported physical activity questionnaires, which have been validated using doubly
224 labelled isotopic water [4], to estimate REE and TEE. As expected energy
225 expenditure was associated with body weight, male sex and younger age group
226 [27]. Patients with higher REE and TEE had greater PNA rate due to increased
227 urinary and peritoneal urea losses However we also noted that although REE was

228 similar, TEE was lower with increasing frailty and co-morbidity, in particular
229 diabetes, and those without employment compared to those patients with lower
230 frailty and co-morbidity scores, who were not diabetic or those with
231 employment. We also found that patients from an Asian background had lower
232 TEE compared to Caucasoids and African-Afro-Caribbean patients. This is in
233 keeping with previous observations of lower energy expenditure, particularly
234 with South Asians, and this has been suggested to be due to differences in
235 terms of body composition, related to brown fat tissue stores [28].

236 We then compared the delivered dialysis dose for the minimum weekly
237 KtVurea target as recommended by clinical practice guidelines [1], using Kt
238 calculated by both the Watson formula [20], and also total body water measured
239 by bioimpedance [29]. We found no significant difference between total body
240 water by either method, although previous reports from haemodialysis patients
241 have reported differences [9]. However the major differences between total
242 body water derived by the Watson formula and bioimpedance were with obese
243 patients with a body mass index of > 35 , and in our study group $< 2\%$ had a body
244 mass index of this level. We adjusted the delivered dialysis dose by both BSA,
245 which is relatively greater for patients with lower total body water, and
246 relatively lower for those with greater total body water and also for both REE
247 and TEE. Adjusting Kt for BSA, which has been advocated for haemodialysis
248 patients, we found that this resulted in a lower dose being delivered to women
249 and those with a high protein nitrogen appearance rate and lower body weight.
250 Whereas adjusting for REE, then female patients, and those who were younger,

251 weighed less, and who had lower protein nitrogen appearance along with those
252 with frailty and co-morbidity scores, and other ethnicities than Asian all
253 received relatively less delivered dialysis. When Kt was adjusted for TEE, then
254 women, younger patients and those weighing less, who were employed, and those
255 with less frailty, in particular those with diabetes, all would receive less
256 delivered dialysis dosing compared to men, heavier patients, those without
257 employment and the more frail, co-morbid patient and those with diabetes.

258 Previous studies targeting a dialysis dose defined by a weekly KtVurea
259 for peritoneal dialysis patients have not shown an advantage for one target
260 compared to another [3,4]. Our study shows that achieving the same urea
261 clearance does not equate to the same delivered dose of dialysis, and as such
262 potentially adds explanation as to why prospective studies have failed to show a
263 significant benefit for one KtVurea target for all patients. Although we
264 accepted that using Kt/Vurea for dialysis dosing has some limitations [31], more
265 recent observational studies have suggested an advantage for adjusting Kt for
266 BSA [30]. However we found that although adjusting for BSA detected a
267 difference between sexes and body weight, those who had higher nitrogen
268 appearance rates. Whereas in particular adjusting for TEE showed that in
269 addition, younger fitter patients received relatively less dialysis dose delivered
270 compared to older, more frail, co-morbid and diabetic patients. As such we
271 suggest that a single Kt/Vurea target dose is not applicable to all patients, and
272 the dose of dialysis should be increased for those who are more physically
273 active with greater TEE.

274

275 The authors have no conflict of interest

276 None of the data contained in this report has been previously published in whole
277 or part form

278

279 Funding grant British Renal Society

280 Dr El-Kateb was awarded a scholarship by the International Society of
281 Nephrology

282

283

284 References

- 285 **1.** Woodrow G, Davies SJ. Peritoneal Dialysis (PD) (Guidelines PD 3.1 -
286 3.3).<http://www.renal.org/guidelines/modules/peritoneal-dialysis-in-ckd#sthash.Br67xjah.dpuf>
287
- 288 **2.** Jansen MA, Termorshuizen F, Korevaar JC, Dekker FW, Boeschoten E,
289 Krediet RT. Predictors of survival in anuric peritoneal dialysis patients.
290 *Kidney Int.* 2005;68(3):1199-205
- 291 **3.** Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J,
292 Mujais S; Mexican Nephrology Collaborative Study Group. Effects of
293 Increased Peritoneal Clearances on Mortality Rates in Peritoneal Dialysis:
294 ADEMEX, a Prospective, Randomized, Controlled Trial. *J Am Soc Nephrol*
295 2002;13(5):1307-20
- 296 **4.** Lo WK, Ho YW, Li CS, Wong KS, Chan TM, Yu AW, Ng FS, Cheng IK.
297 Effect of Kt/V on survival and clinical outcome in CAPD patients in a
298 randomized prospective study. *Kidney Int* 2003;64(2):649-56
- 299 **5.** Paniagua R, Amato D, Vonesh E, Guo A, Mujais S; Mexican Nephrology
300 Collaborative Study Group. Health-related quality of life predicts
301 outcomes but is not affected by peritoneal clearance: The ADEMEX trial.
302 *Kidney Int.* 2005;67(3):1093-104
- 303 **6.** Churchill DN, Taylor DW, Keshaviah PR. Adequacy of dialysis and nutrition
304 in continuous peritoneal dialysis: association with clinical outcome. *J Am*
305 *Soc Nephrol* 1996;7:198-207
- 306 **7.** Bargman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study
307 Group. Relative contribution of residual renal function and peritoneal
308 clearance to adequacy of dialysis: a reanalysis of the CANUSA study. *J*
309 *Am Soc Nephrol.* 2001;12(10):2158-62
- 310 **8.** Watson PE, Watson ID, Batt RD. Total body water volume for adult males
311 and females estimated from simple anthropometric measurements. *Am J*
312 *Clin Nutr* 1980;33:27-39
- 313 **9.** Davenport A. Differences in prescribed Kt/V and delivered haemodialysis
314 dose--why obesity makes a difference to survival for haemodialysis
315 patients when using a 'one size fits all' Kt/V target. *Nephrol Dial*
316 *Transplant.* 2013;28 Suppl 4:iv219-23

- 317 **10.** Davenport A, Hussain Sayed R, Fan S. The effect of racial origin on total
318 body water volume in peritoneal dialysis patients. *Clin J Am Soc Nephrol.*
319 2011 ;6(10):2492-8
- 320 **11.** Davenport A, Willicombe MK. Does diabetes mellitus predispose to
321 increased fluid overload in peritoneal dialysis patients? *Nephron Clin Pract.*
322 2010;114(1):c60-66
- 323 **12.** Spalding EM, Chandna SM, Davenport A, Farrington K: Kt/V
324 underestimates the haemodialysis dose in women and small men. *Kidney*
325 *Int*, 2008;74: 348-355
- 326 **13.** Daugirdas JT, Levin NW, Kotanko P, Depner TA, Kuhlmann MK, Chertow
327 GM, Rocco MV: Comparison of proposed alternative methods for rescaling
328 dialysis dose: resting energy expenditure, high metabolic rate organ mass,
329 liver size, and body surface area. *Semin Dial*, 2008;21: 377-384
- 330 **14.** Bazanelli AP, Kamimura MA, da Silva CB, Avesani CM, Lopes MG, Manfredi
331 SR, Draibe SA, Cuppari L. Resting energy expenditure in peritoneal
332 dialysis patients. *Perit Dial Int.* 2006;26(6):697-704
- 333 **15.** Wang AY, Sea MM, Tang N, Sanderson JE, Lui SF, Li PK, Woo J. Resting
334 energy expenditure and subsequent mortality risk in peritoneal dialysis
335 patients. *J Am Soc Nephrol.* 2004;15(12):3134-43
- 336 **16.** Sridharan S, Wong J, Vilar E, Farrington K. Comparison of energy
337 estimates in chronic kidney disease using doubly-labelled water. *J Hum*
338 *Nutr Diet.* 2015 Jul 15 PMID: 26173618
- 339 **17.** Bergström J, Heimbürger O, Lindholm B. Calculation of the protein
340 equivalent of total nitrogen appearance from urea appearance. Which
341 formulas should be used? *Perit Dial Int.* 1998;18(5):467-73
- 342 **18.** Sridharan S, Berdeprado J, Vilar E, Roberts J, Farrington K: A self-
343 report comorbidity questionnaire for haemodialysis patients. *BMC*
344 *Nephrol*, 2014;15: 134
- 345 **19.** Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I,
346 Mitnitski A. A global clinical measure of fitness and frailty in elderly
347 people. *CMAJ.* 2005;173(5):489-95
- 348 **20.** Watson PE, Watson ID, Batt RD. Total body water volume for adult males
349 and females estimated from simple anthropometric measurements. *Am J*
350 *Clin Nutr* 1980;33:27-39
- 351 **21.** Davenport A. Effect of intra-abdominal dialysate on bioimpedance-
352 derived fluid volume status and body composition measurements in
353 peritoneal dialysis patients. *Perit Dial Int.* 2013;33(5):578-9
- 354 **22.** Fürstenberg A, Davenport A. Assessment of body composition in
355 peritoneal dialysis patients using bioelectrical impedance and dual-energy
356 x-ray absorptiometry. *Am J Nephrol.* 2011;33(2):150-6
- 357 **23.** McCafferty K, Fan S, Davenport A. Extracellular volume expansion,
358 measured by multi-frequency bioimpedance, does not help preserve
359 residual renal function in peritoneal dialysis patients. *Kidney Int.* 2013
- 360 **24.** Dombros N, Dratwa M, Feriani M, Gokal R, Heimbürger O, Krediet R, Plum
361 J, Rodrigues A, Selgas R, Struijk D, Verger C; EBPg Expert Group on

- 362 Peritoneal Dialysis. European best practice guidelines for peritoneal
 363 dialysis. 7 Adequacy of peritoneal dialysis. *Nephrol Dial Transplant*.
 364 2005;20 Suppl 9:ix21-ix23
- 365 **25.** Vilar E, Machado A, Garrett A, Kozarski R, Wellsted D, Farrington K:
 366 Disease-Specific Predictive Formulas for Energy Expenditure in the
 367 Dialysis Population. *J Ren Nutr*. 2014; 24: 243-251
- 368 **26.** Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR, Jr.,
 369 Tudor-Locke C, Greer JL, Vezina J, Whitt-Glover MC, Leon AS: 2011
 370 Compendium of Physical Activities: A Second Update of Codes and MET
 371 Values. *Med Sci Sports Exerc*.2011; 43: 1575-1581
- 372 **27.** Finkel T. The metabolic regulation of aging. *Nat Med*. 2015;21(12):1416-
 373 23
- 374 **28.** Boon MR, Bakker LE, van der Linden RA, van Ouwkerk AF, de Goeje PL,
 375 Counotte J, Jazet IM, Rensen PC. High prevalence of cardiovascular
 376 disease in South Asians: Central role for brown adipose tissue? *Crit Rev*
 377 *Clin Lab Sci*. 2015;52(3):150-7
- 378 **29.** Davies SJ, Davenport A. The role of bioimpedance and biomarkers in
 379 helping to aid clinical decision-making of volume assessments in dialysis
 380 patients. *Kidney Int*. 2014;86(3):489-96
- 381 **30.** Ramirez SP, Kapke A, Port FK, Wolfe RA, Saran R, Pearson J, Hirth RA,
 382 Messana JM, Daugirdas JT. Dialysis dose scaled to body surface area and
 383 size-adjusted, sex-specific patient mortality. *Clin J Am Soc Nephrol*.
 384 2012;7(12):1977-87.
- 385 **31.** Daugirdas JT. Kt/V (and especially its modifications) remains a useful
 386 measure of haemodialysis dose. *Kidney Int*. 2015;88(3):466-73

387
 388
 389
 390
 391
 392

393 Figure 1: Relationship between body surface area (BSA) and Watson total body
 394 water for man and women.

395 .

396 Figure 2: Bland Altman analysis of total body water (TBW) measured by
 397 bioimpedance or calculated by Watson equation. Mean difference 0.72 L (95%
 398 limits of agreement -9.2 to +10.7 L).

399

400 Figure 3: Adjusted daily urea clearance according to body weight. Fixed weekly
 401 Kt of 1.7urea adjusted for body surface area (BSA) and resting energy (REE)
 402 and total energy (TEE) expenditure using Watson total body water (W) or
 403 bioimpedance measured total body water (BIA).* p <0.05, and **p<0.01 vs weight
 404 < 64 kg after Bonferroni correction.

405
 406

407 Table 1. Estimates of daily resting energy expenditure (REE) and total energy
 408 expenditure (TEE) in patients according to age, co-morbidity, frailty and
 409 ethnicity groupings. Daily protein nitrogen appearance (PNA) g/day. Results
 410 expressed as mean \pm standard deviation, or median (interquartile range). * $p < 0.05$,
 411 ** $p < 0.01$ comparing groups, adjusted for multiple comparisons (Bonferroni
 412 method).
 413

variable	REE kcal/day	TEE kcal/day
male	1597 \pm 217	2029 \pm 423
female	1412 \pm 240**	1868 \pm 377*
Age < 65 years	1646 \pm 209	2173 \pm 392
Age > 65 years	1408 \pm 211**	1750 \pm 314**
Non-diabetic	1522 \pm 233	2021 \pm 435
diabetic	1556 \pm 254	1893 \pm 366*
employed	1577 \pm 237	2305 \pm 511
not employed	1523 \pm 242	1890 \pm 340**
Low comorbidity	1532 \pm 245	2012 \pm 441
High comorbidity	1539 \pm 231	1862 \pm 300
Low frailty score	1533 \pm 227	2049 \pm 453
High frailty score	1535 \pm 256	1894 \pm 353*
Weight < 64 kg	1305 \pm 151	1706 \pm 306
Weight 64-80 kg	1514 \pm 142**	1973 \pm 414**
Weight > 80 kg	1775 \pm 159**	2233 \pm 339**
PNA < 60 g/day	1450 \pm 214	1826 \pm 317
PNA > 60 g/day	1622 \pm 229**	2133 \pm 438**
Non Asian	1561 \pm 225	2060 \pm 462
Asian	1522 \pm 243	1866 \pm 359*

414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430

431 Table 2. Comparison for a fixed total weekly Kt/V of 1.7 (urea clearance
 432 L/m²/day, or ml urea clearance/kcal/day) adjusted for body surface area (BSA),
 433 resting energy expenditure (REE), total energy expenditure (TEE) for peritoneal
 434 dialysis patients comparing sexes, age (years), diabetic, employment status, and
 435 co-morbidity, weight and ethnicity. Diabetic (DM), High (H) and Low (L) frailty,
 436 co-morbidity (Comorb), protein nitrogen appearance (PNA) employed (employ +),
 437 not employed (employ -), ethnicity (Asian vs other races). *p<0.05 **p<0.01 after
 438 Bonferroni post hoc correction for multiple testing.
 439

variable	Kt/BSA	Kt/REE _w	Kt/TEE _w	Kt/REE _{BIA}	Kt/TEE _{BIA}
Male	5.13±0.36	6.15±9.61	4.96±0.71	6.23±0.62	4.93±0.70
Female	4.42±0.40**	5.50±0.41**	4.23±0.65**	5.64±0.64**	4.27±0.71**
Age < 65	4.83±0.46	5.58±0.55	4.29±0.53	5.93±0.73	4.52±0.81
Age > 65	4.95±0.42	6.38±0.49**	5.18±0.61**	6.12±0.62	4.93±0.65**
DM yes	4.96±0.45	6.03±0.58	5.00±0.69**	5.92±0.65	4.93±0.69*
DM no	4.84±0.46	5.90±0.66	4.53±0.82	6.06±0.71	4.57±0.78
H frailty	4.91±0.47	6.06±0.66	4.96±0.75	6.01±0.61	4.90±0.71
L frailty	4.86±0.43	5.85±0.60*	4.46±0.78**	6.01±0.75	4.54±0.78**
HComorb	4.99±0.43	6.19±0.63	5.14±0.66	5.91±0.63	4.90±0.63
LComorb	4.85±0.45	5.87±0.62**	4.55±0.80**	6.05±0.71	4.62±0.81
Employ -	4.89±0.43	5.99±0.61	4.87±0.72	5.96±0.73	4.81±0.75
Employ +	4.89±0.54	5.82±0.71	4.07±0.82**	6.19±0.51	4.31±0.72**
H PNA	4.79±0.40	5.91±0.62	4.75±0.78	5.77±0.70	4.56±0.70
L PNA	4.95±0.48*	5.98±0.68	4.62±0.87	6.23±0.59*	4.81±0.81
Asian	4.87±0.46	5.97±0.65	4.67±0.85	6.10±0.65	4.71±0.76
Other	4.87±0.42	5.90±0.60	4.79±0.69	5.79±0.76*	4.64±0.80

440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457

458 Table 3. Multivariable step backward models for weekly Kt adjusted for Body
 459 surface area (BSA), resting energy expenditure (REE), and total energy
 460 expenditure (TEE), using both total body water calculated by Watson equation
 461 (W) and measured by bioimpedance (BIA). Unstandardised β (β), standard error
 462 (StE), standardised β (Standard β), 95% Confidence limits (95% CL). Protein
 463 nitrogen accumulation rate (PNA).

464 Adjusted for BSA model r^2 0.60, adjusted 0.59, model adjusted for REE_W r^2 0.60,
 465 adjusted 0.59, model adjusted for REE_{BIA} r^2 0.42, adjusted 0.37, model adjusted
 466 for TEE_W r^2 0.42, adjusted 0.3, and adjusted for TEE_{BIA} r^2 0.35, adjusted 0.33.
 467 Sex (female vs male), age years, high co-morbidity (H).

468

469

	β	StE β	Standard β	t	95% CL	p
Kt _{urea} /BSA						
sex (M)	0.70	0.05	0.77	13.5	0.6-0.87	<0.001
Kt _{urea} /REE _W						
sex (M)	0.58	0.08	0.44	7.5	0.43-0.74	<0.001
age	0.02	0.01	0.54	9.3	0.2-0.25	<0.001
Kt _{urea} /REE _{BIA}						
PNA	0.01	0.01	0.37	4.4	0.01-0.02	<0.001
sex (M)	0.39	0.12	0.28	3.2	0.15-0.63	0.002
age	0.01	0.01	0.19	2.3	0.01-0.01	0.025
Kt _{urea} /TEE _W						
sex (M)	0.59	0.10	0.35	6.1	0.40-0.79	<0.001
age	0.02	0.01	0.44	7.5	0.02-0.013	<0.001
no employment	0.52	0.11	0.26	4.5	0.29-0.74	<0.001
comorbidity H	0.30	0.11	0.16	2.7	0.01-0.52	0.009
diabetic	0.21	0.10	0.12	2.0	0.01-0.41	0.045
Kt _{urea} /TEE _{BIA}						
sex (M)	0.51	0.13	0.33	3.8	0.25-0.77	<0.001
age	0.01	0.01	0.32	7.5	0.01-0.02	<0.001
no employment	0.44	0.15	0.24	3.0	0.15-0.74	0.004

470

471

472

473

474

475

476

477

478

479

480

481

482 Appendix

483

484 Resting Energy Expenditure (REE) was estimated from a newer novel predictive
485 equation which was derived and validated in a cohort of HD patients [18].

486

$$487 \text{ REE} = -2.497 * \text{Age}(\text{years}) * \text{Factor}_{\text{age}} + 0.011 * \text{Height}^{2.023}(\text{cm}) + 83.573 * \\ 488 \text{Weight}^{0.6291}(\text{kg}) + 68.171 * \text{Factor}_{\text{sex}}$$

489

490 where Factor age is 0 if age <65 and 1 if ≥65 and Factor sex is 0 if female and 1
491 if male

492

493 Physical activity data - Each reported activity was assigned a Metabolic
494 Equivalent of Task (MET) value as per the Compendium of Physical Activities
495 [19]. Sleep time per day was assumed to be 8 hours and any unreported time
496 during the day was assumed as the time performing light activities at home. A
497 Mean daily MET value was calculated.

498

499 Total Energy Expenditure (TEE) was estimated from the following equation.

$$500 \text{ TEE} = \text{REE} * \text{Mean Daily MET}$$

501 .

502

503

504

505

506

507

508

509

510

511

512

513